2023
25 January, 2023
CFO acquired shares in FluoGuide
FluoGuide A/S (“FluoGuide” or the “Company”) announce that the CFO of FluoGuide, Henrik Hang, has acquired...
Copenhagen, Denmark, 9 January 2023 - FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the positive...
2022
In Q3 2022, FluoGuide made important progress and received approvals from Danish authorities to initiate the clinical phase IIb trial...
21 November, 2022
FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer
The phase IIa trial is designed to obtain proof-of-concept in head and neck cancer for our uPAR platform technology used to guide surgical...
8 November, 2022
FluoGuide reaches milestone with FG001 for phase III clinical supply
FluoGuide has successfully collaborated with its supplier PolyPeptide since the very first synthesis of the FG001 API (Active Pharmaceutical...
FluoGuide has evaluated data from 8 patients in the exploratory phase IIa trial in patients with non-small cell lung cancer (NSCLC)...
20 October, 2022
FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer
In the phase IIb trial, FG001 is being tested as a standalone treatment compared to Gliolan (5-ALA), which is the only approved product...
6 October, 2022
Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022
The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon...
3 October, 2022
The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress
Andreas Kjaer, Professor and CSO at FluoGuide presented the excellent phase I/IIa clinical data of FG001 in aggressive brain cancer...
Calendar &
upcoming reports
22 February 2023
Life Science Investor Konference | Økonomisk Ugebrev
28 February 2023
21 March 2023
31 May 2023
30 August 2023